Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN87426672) titled 'Anti-depressants for depression in Huntington's disease' on Oct. 2.
Study Type: Interventional
Study Design:
Double-blind randomized controlled feasibility trial (Treatment, Efficacy)
Primary Sponsor: Cardiff University
Condition:
Antidepressant treatment for depression in individuals with a confirmed genetic diagnosis of Huntington's Disease.
Mental and Behavioural Disorders
Intervention:
Randomisation will take place online through a bespoke system built for the trial to maintain the blind.
Participants will be randomised to receive either 50mg of sertraline or Placebo daily for 6 months. Participants wi...